Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Centessa Pharmaceuticals ( (CNTA) ) has issued an update.
On May 27, 2025, Centessa Pharmaceuticals appointed Raphael Deferiere as Chief Accounting Officer, succeeding John Crowley in this role. Deferiere, a seasoned professional from Ernst & Young, brings extensive experience to the company, potentially strengthening its financial oversight. His compensation package includes a base salary, an annual bonus, and stock options, indicating the company’s investment in securing top talent for its financial leadership team.
The most recent analyst rating on (CNTA) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Centessa Pharmaceuticals stock, see the CNTA Stock Forecast page.
Spark’s Take on CNTA Stock
According to Spark, TipRanks’ AI Analyst, CNTA is a Underperform.
Centessa Pharmaceuticals has a low overall stock score due to significant financial challenges, including ongoing losses, negative cash flow, and a bearish technical outlook. The lack of profitability reflected in the negative P/E ratio further contributes to the low score. Investors should be cautious, considering the company’s need for additional funding to sustain operations in the capital-intensive biotechnology industry.
To see Spark’s full report on CNTA stock, click here.
More about Centessa Pharmaceuticals
Centessa Pharmaceuticals operates in the pharmaceutical industry, focusing on developing innovative medicines. The company is committed to advancing its pipeline of therapies to address unmet medical needs.
Average Trading Volume: 926,363
Technical Sentiment Signal: Sell
Current Market Cap: $1.71B
Find detailed analytics on CNTA stock on TipRanks’ Stock Analysis page.